Welcome to the international HTA database

Showing [21797 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (colorectal cancer) - Benefit assessment according to § 35a SGB V]
2021	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (colorectal cancer) - Addendum to Commission A21-36]
2017	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (classical Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (cervical cancer) - Benefit assessment according to § 35a SGB V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (cervical cancer) - Addendum to Commission A22-70]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (breast cancer) - Benefit assessment according to § 35a Social Code Book V]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (breast cancer) - Addendum to Commission A22-63]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (bile cancer) - Benefit assessment according to § 35a SGB V]
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab - Addendum to Commission A15-33]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pelvic vein embolization or sclerotherapy in pelvic congestion syndrome]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pelvic vein embolization or sclerotherapy in pelvic congestion syndrome]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pegvaliase in phenylketonuria]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pegvaliase (phenylketonuria) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pegunigalsidase alfa (Fabry disease) – Benefit assessment according to §35a Social Code Book V]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pegcetacoplan (paroxysmal nocturnal haemoglobinuria, pretreated patients) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2009	Committee for New Health Technology Assessment (CNHTA)	[PDGFRA gene exon 12,18 mutation sequencing test]
2023	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[PCR type nucleic acid amplification tests in blood applied to rapid etiological diagnosis in suspected sepsis: assessment of its diagnostic and prognostic utility, safety, and economic and organizational implementation considerations]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Pazopanib (Votrient) for the treatment of patients with advanced renal cell carcinoma]
2010	Committee for New Health Technology Assessment (CNHTA)	[PAX6 gene, mutation[sequencing]]
2021	Institute for Clinical Effectiveness and Health Policy (IECS)	[Patisiran and inotersen in hereditary transthyretin-mediated amyloidosis]
2024	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Patisiran (hereditary transthyretin-mediated amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code Book V]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Patisiran (hereditary transthyretin amyloidosis with polyneuropathy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Patiromer (hyperkalaemia) - Benefit assessment according to §35a Social Code Book V]
2007	The Netherlands Organisation for Health Research and Development (ZonMw)	[Patients' and general practitioners' preferences for osteoporosis treatment ancillary study of 'case finding in osteoporosis: how to implement current guidelines?']
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Patients with hip fracture from low-impact trauma: clinical management of anti-osteoporotic pharmacological treatment to prevent new fractures]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Patient-specific blister packaging - rapid report]
2009	The Netherlands Organisation for Health Research and Development (ZonMw)	[Patient-centred implementation of elective single embryo transfer (eSET) in in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI)]
2013	Institut national d'excellence en sante et en services sociaux (INESSS)	[Patient-based funding: a literature review of experiences in other countries]
2008	The Netherlands Organisation for Health Research and Development (ZonMw)	[Patient safety/medication safety: the impact of computerized physician order entry on medication error prevention in hospitalized patients]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Patient safety program in pain management units]
2008	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Patient involvement between ideals and reality]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Patient information on interstitial low-dose-rate brachytherapy for localized prostate cancer - addendum to commission N17-04]
2018	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Patient Health Questionnaire- 9, PHQ-9, for depression screening in adults]
2009	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Patient education - a health technology assessment]
2011	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Patient decision aids tool for prostate cancer]
2012	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Patient decision aids tool for colorectal cancer]
2010	Unidad de Evaluacion de Tecnologias Sanitarias (UETS)	[Patient decision aids tool for breast cancer]
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pasireotide (new therapeutic indication) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2012	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pasireotide - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment)]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pascal laser use in the treatment of retinal pathology]
2012	National Evidence-based Healthcare Collaborating Agency (NECA)	[Part Ⅲ. A study on the current status and treatment promotion of comorbid depression among patients with cancer or patients with diabetes mellitus]
2012	National Evidence-based Healthcare Collaborating Agency (NECA)	[Part Ⅱ. Study on adolescent depression and suicide]
2012	National Evidence-based Healthcare Collaborating Agency (NECA)	[Part Ⅰ. A study on current status and unmet need for the treatment of psychiatric disorders in Korea]
2007	Unit of Health Economics and Technology Assessment in Health Care (HunHTA)	[Parenteral methotrexate in patients with rheumatoid arthritis: systematic review, crossectional study and economic evaluation]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Parenteral infusion pump during general hospital ward]
2021	Austrian Institute for Health Technology Assessment (AIHTA)	[Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Parent information on newborn screening using pulse oximetry; addendum to commission S13-01]
2008	Committee for New Health Technology Assessment (CNHTA)	[Parainfluenza virus 1,2,3 RT-nested PCR]
2015	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Panobinostat: assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Panel antibody detection for idiopathic inflammatory myopathies]
2012	Basque Office for Health Technology Assessment (OSTEBA)	[Palliative care requirements in the case of non-oncological diseases. A qualitative study from the perspective of professionals, patients and carers`]
2022	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[Palliative care day centre service offer for users and caregivers]
2014	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Palliation vs. curation - an attempt to clarify terms]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Palivizumab for the prevention of respiratory syncytial virus lower respiratory tract infections]
2017	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Palbociclib (breast cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Palbociclib (breast cancer) - Benefit assessment according to § 35a SGB V]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Palbociclib (breast cancer) - Addendum to Commission A18-63]
2017	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Palbociclib (breast cancer) - Addendum to commission A16-74]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Palbociclib (breast cancer, combination with an aromatase inhibitor) - Addendum to Commission A22-66]
2006	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Pain school - a health technology assessment]
2009	National Evidence-based Healthcare Collaborating Agency (NECA)	[Pain relief effects of injection therapy for patients with chronic back pain]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Paediatric triage systems in hospital emergency department: reliability and validity]
2006	Unit of Health Economics and Technology Assessment in Health Care (HunHTA)	[Paclitaxel-Eluting Coronary Stent System in cardiovascular treatment; systematic review of the clinical and economic literature]
2011	Finnish Office for Health Care Technology Assessment (Finohta)	[Paclitaxel-coated balloon angioplasty in the treatment of coronary artery disease and peripheral artery stenosis – a systematic review]
2013	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[P16/Ki-67 dual stain in the triage of PAPIII/IIID cytology in cervical cancer screening]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ozone therapy]
2006	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Ozone therapy in the treatment of herniated disc and other painful conditions of the lumbar]
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ozone therapy for the treatment of lumbar disc disease]
2006	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Ozone therapy for the treatment of intervertebral herniated disk]
2005	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Ozone therapy for the treatment of dental caries]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ozanimod (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ozanimod (multiple sclerosis) - Addendum to Commission A20-59]
2010	Andalusian Health Technology Assessment Area (AETSA)	[Oxygen carriers. Production of red blood cells from human embryonic stem cells]
2009	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Overweight prevention in adolescents and children (behavioural and environmental prevention]
2009	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Overweight prevention in adolescents and children (behavioural and environmental prevention]
2009	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Overweight in the teenager population: quality of life, access to health care services and cost-effectiveness of interventions]
2013	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Overweight and obesity: the efficacy of diets for weight maintenance after weight loss]
2012	Institut national d'excellence en sante et en services sociaux (INESSS)	[Overview of the use of antihypertensive agents by adults covered by the Québec public prescription drug insurance plan]
2013	Institut national d'excellence en sante et en services sociaux (INESSS)	[Overview of the drugs used by children and adolescents diagnosed with autism spectrum disorder who are covered by the Public Prescription Drug Insurance Plan]
2013	Institut national d'excellence en sante et en services sociaux (INESSS)	[Overview of dabigatran usage among people insured by the public prescription drug insurance plan]
2022	Norwegian Institute of Public Health (NIPH)	[Overdose warning systems: a single technology assessment - mapping]
2011	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Over-, under- and misuse of pain treatment in Germany]
2023	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Ovarian tissue cryopreservation and transplantation in patients with cancer or benign diseases to fertility preservation]
2008	Haute Autorite de sante (HAS)	[Ovarian drilling by laparoscopy or transvaginal fertiloscopy]
2010	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Outpatient pulmonary rehabilitation - rehabilitation models and shortcomings in outpatient aftercare]
2015	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Outpatient neurological rehabilitation: goal attainment in stroke patients. Systematic review]
2012	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Outpatient cardiac rehabilitation. part V: study protocol, multi-centre prospective controlled observational study with two parallel groups on outpatient cardiac phase III rehabilitation]
2016	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Outpatient cardiac rehabilitation part VII: Economic Evaluation]
2016	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Outpatient cardiac rehabilitation part VI: prospective multi-centre cohort study (comparing patients with and without phase III)]
2011	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Outpatient cardiac rehabilitation Part 4: Options for carrying out a prospective study]
2010	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Outpatient cardiac rehabilitation Part 3b: Retrospective cohort study (with/without phase III rehabilitation) - application of the evaluation plan]
2010	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Outpatient cardiac rehabilitation Part 3a: Retrospective cohort study (with/without phase III rehabilitation) - explorative analysis and developing of an evaluation plan]
2011	National Evidence-based Healthcare Collaborating Agency (NECA)	[Outcomes research of preventive procedures in unruptured intracranial aneurysm]
2013	National Evidence-based Healthcare Collaborating Agency (NECA)	[Outcomes research for complications of inhaled bronchodilators/corticosteroids]
2007	Andalusian Health Technology Assessment Area (AETSA)	[Outcomes of treatments for stuttering]